Investor Relations

Corporate Profile

Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.

Stock Chart

Copyright West LLC. Minimum 15 minutes delayed.

Stock Quote

News Releases
January 3, 2019
Neon Therapeutics Provides Business Update and Outlook for 2019
CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today provided a business update and outlook for 2019. “We have an exciting year ahead of us in 2019, with multiple data
November 16, 2018
Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe
CAMBRIDGE, Mass. , Nov. 16, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics (Nasdaq: NTGN) has been named one of the top places to work in Massachusetts by The Boston Globe , an honor awarded based on employee feedback. The Top Places to Work awards recognize the most admired workplaces in the state, as